AbbVie Inc. (ABBV)
|Address:1 N Waukegan Rd
North Chicago, Illinois 60064-1802
|Phone||847 932 7900|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.
In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production.
The company was incorporated in 2012 and is based in North Chicago, Illinois.
|Richard A. Gonzalez||Chairman and Chief Executive Officer|
|Dr. Michael E. Severino||Vice Chairman and Pres|
|Robert A. Michael||Executive Vice President and Chief Financial Officer|
|Laura J. Schumacher||Vice Chairman of External Affairs, Chief Legal Officer and Corporate Secretary|
|Dr. Azita Saleki-Gerhardt||Executive Vice President of Operations|
|Dr. Thomas J. Hudson||Senior Vice President of Research & Development and Chief Scientific Officer|
|Elizabeth Shea||Vice President of Investor Relations|
|Timothy J. Richmond||Executive Vice President and Chief Human Resources Officer|
|Dr. Scott C. Brun M.D.||Vice President of Scientific Affairs and Head of AbbVie Ventures|
|Henry O. Gosebruch||Executive Vice President and Chief Strategy Officer|